Medindia
Advertisement

Modern Anticancer Vaccines Enhanced With Personalization Techniques

by Colleen Fleiss on December 21, 2018 at 8:52 AM

Modern Anticancer Vaccines Enhanced With Personalization Techniques
Anticancer vaccines have now gained a fresh lease of life with techniques and methods personalized to individual patients. Cutting edge developments in this re-energised field were revealed at the ESMO Immuno-Oncology Congress in Geneva, Switzerland.

The original anticancer vaccines, launched in the late 1990s, were based on shared tumour antigens and failed to induce a potent immune response. After decades of disappointing results, a number of advances have sparked a renewed interest in the field. These include new technologies and prediction algorithms to personalise vaccines, and the introduction of checkpoint inhibitors for combination therapy.
Advertisement


Dr Michal Bassani-Sternberg, Group Leader, Immunopeptidomics, Hi-TIDe Laboratory, Department of Oncology, University of Lausanne, Switzerland, and the Ludwig Institute for Cancer Research in Lausanne, said: "The 'Modern anticancer vaccines' session at the ESMO Immuno-Oncology Congress was timely since there is again a flurry of activity around anticancer vaccines. We can now customise vaccines for each patient based on the genomic information in their tumour, and the early results are promising."

Bassani-Sternberg said: "We have a good way to fish out and propose targets for vaccination. The first trials were published last year and showed that the selected targets were immunogenic, meaning that vaccination induced immune responses or amplified existing immune responses against these neoantigens. In addition, the vaccines worked well with checkpoint inhibitors. We now need to see if vaccination against neoantigens leads to tumour regression in a larger cohort of patients."
Advertisement

Neoantigens were explored in a dedicated session at the ESMO Immuno-Oncology Congress (2) and were discussed in the session on modern anticancer vaccines, (3) which also described the role of other vaccine targets. These include oncogenic proteins such as HER2, pathogens like the human papilloma virus (HPV), and prostate-specific antigens. These shared antigens are also being tested in combination with checkpoint inhibitors.

Bassani-Sternberg said the combination of modern anticancer vaccines and checkpoint inhibitors appears to generate the most effective immune response. "Vaccines can induce new responses in patients with 'cold tumours' which lack immune cells, thus making the environment receptive to checkpoint inhibitors," she said.

Numerous questions remain unanswered, such as when to vaccinate patients. Should this be immediately after surgery, when there are few tumour cells left, or beforehand? Should vaccines be administered against primary tumours and metastases? Will it be necessary to give new vaccines every few months as tumours evolve naturally and in response to treatment? How and when should vaccines be combined with other therapies? And while the choice of neoantigen seems crucial, decisions are also needed on the formulation (protein-based, RNA, cell-based), delivery vehicle (liposomes, virosomes, emulsions), route of administration (intranodal, intradermal), and adjuvants.

But despite these questions, vaccination appears feasible. The technology to develop vaccines is available and getting better, the vaccines are safe and immunogenic, and there is openness from the regulators to testing vaccines in clinical trials. Bassani-Sternberg said: "We are counting on new technologies that have now matured. Next generation sequencing has made identification of vaccine targets more efficient, reliable, and cheaper. The algorithms to interpret this data are benchmarked and validated for predicting which targets are most likely to be immunogenic. Sequencing technologies are only going to get better and prediction tools will become even more accurate."

"There is great hope for vaccines," she continued. "And they have the potential to benefit most patients because almost all tumours have targets that could be vaccinated."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Stroop Effect
Plant-Based Diet may Reduce the Risk of COVID-19
Lower Respiratory Tract Infections Linked to Obstructive Sleep Apnea in Children
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Vaccination for Children Neutropenic Sepsis 

Recommended Reading
Potency of Anticancer Drug Increased by Carboranes
In a new effort, medicinal chemists added a special structure to an anticancer drug and developed a ...
Quiz on Chemotherapy Drugs
Chemotherapy involves the administration of medications to fight cancer. Test your knowledge on .....
New Generation of RNA Based Anticancer Drugs
RNA nanotechnology used to produce therapy-loaded extracellular vesicles that successfully targeted ...
Scientists Find Way for Anticancer Vaccines
A report published in The Journal of Experimental Medicine suggests that scientists have fo...
Neutropenic Sepsis
Neutropenic sepsis is a potentially life-threatening condition when a patient with low neutrophil co...
Vaccination for Children
Vaccines are biological products that impart immunity to the recipient. Vaccines may be live attenua...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use